source
- AstraZeneca launches $1.5 billion annual cost-saving plan to offset late-stage trial setbacksAstraZeneca announced a new cost‑saving initiative targeting $1.5 billion of annual expenses. The move follows a series of late‑stage clinical trial failures that have pressured the company's pipe…
- Setara Biosciences raises $90 million to advance rare-disease pipeline after Actio spin-outActio Biosciences shipped its precision epilepsy drug to Jazz Pharmaceuticals and then separated the rest of its genetics-driven pipeline into a new company called Setara Biosciences. Setara has s…